Retroperitoneal Lymphadenectomy: Indications, Complications and Expectations
- 1 January 1977
- book chapter
- Published by Springer Nature
- No. 60,p. 221-230
- https://doi.org/10.1007/978-3-642-81095-4_24
Abstract
The rapid development of multimodal therapy in the management of non-seminomatous testicular tumors demands a reappraisal of the role of lymphadenectomy in this disease. Radiotherapy has been used almost exclusively for the past 25 years in England and many European countries for treatment of all patients with testicular carcinoma, regardless of histologic type (1, 9, 10, 19, 26, 27); whereas, in the USA, lymphadenectomy either alone (29) or combined with irradiation (3, 7, 15, 24) has remained the popular choice. The purpose of this presentation is to report our experience gained from performing 152 retro-peritoneal lymphadenectomies over the past 18 years and is an attempt at the present time to answer CALDWELL’s (2) challenge: “Why retroperitoneal lymphadenectomy?”Keywords
This publication has 23 references indexed in Scilit:
- BENIGN TRANSFORMATION OF TESTICULAR CARCINOMA BY CHEMOTHERAPYThe Lancet, 1975
- SUPERVOLTAGE RADIATION THERAPY OF THE TESTICULAR TUMORSAmerican Journal of Roentgenology, 1973
- RADIOTHERAPY FOR PATIENTS WITH TUMOURS OF THE TESTICLEBritish Journal of Urology, 1971
- MATURATION IN HUMAN TUMOURSThe Lancet, 1969
- Why Retroperitoneal Lymphadenectomy for Testicular Tumors?Southern Medical Journal, 1969
- Treatment of Tumours of the TestisBMJ, 1963
- RADIOTHERAPY IN THE TREATMENT OF PATIENTS WITH SEMINOMAS AND TERATOMAS OF THE TESTICLE1British Journal of Urology, 1962
- HYPERTENSION FOLLOWING X-IRRADIATION OF THE KIDNEYSThe Lancet, 1958
- RADIOTHERAPY AND TESTICULAR NEOPLASMSThe Lancet, 1951
- On malignant tumours of the testicleBritish Journal of Surgery, 1947